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A large number of drugs have been used to treat recurrent ovarian cancer, yet there are few data that guide the physician’s choice.
Typically, the decision to re-treat with platinum-based therapy depends on the progression-free interval. However, the optimum
agent for the treatment of platinum-resistant or refractory disease is not defined. In this study, we investigated the efficacy of oral
melphalan in patients who have platinum refractory or resistant disease. A retrospective analysis was performed on 22 patients with
ovarian carcinomas who had relapsed within 6 months of their platinum-based chemotherapy and were treated with oral melphalan.
No objective responses were seen and the median overall survival was 3 months from commencement of therapy. Although the
treatment was generally well tolerated, only two of the 22 patients managed to complete the planned six cycles of treatment. At the
time of analysis, only two patients were alive. Other nonplatinum compounds have demonstrated response rates in the region of 20%
in similar patient populations and it is unlikely that any positive responses could have been missed by chance (95% CI 0–15.4). The
results of this study serve to eliminate oral melphalan as a treatment option in patients with platinum-resistant or refractory ovarian
carcinoma.
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Ovarian cancer is the leading cause of mortality from gynaecolo-
gical malignancies in the Western world (Greenlee et al, 2001).
Over 70–80% of patients present with advanced disease (stage
III/IV) at diagnosis and the majority of these patients will develop
recurrent disease. The most important predictive factor for
response at relapse is the progression-free interval (PFI), a
surrogate marker for intrinsic chemosensitivity (Blackledge et al,
1989; Markman et al, 1991). At relapse, patients can be separated
into platinum-sensitive (PFI 46 months) and platinum-resistant
(PFI o6 months) or platinum-refractory (no PFI) subsets. In
general, patients with platinum-sensitive disease can be rechal-
lenged with a platinum compound and nonplatinum agents are
reserved for patients with platinum-resistant/refractory disease.
Over the last decade, several new compounds have been developed
with activity in patients with platinum-resistant/refractory disease.
These include the taxanes, topotecan, liposomal doxorubicin and
oxaliplatin among others. These agents are associated with
response rates in the region of 20% with response durations of
6–8 months in platinum-resistant/ refractory patients (Gore,
2001). In addition, combination treatment regimens have reported
higher response rates (Meyer et al, 2001; van der Burg et al, 2002).
Alkylating agent-based chemotherapy was the treatment of
choice for primary epithelial ovarian carcinomas prior to the
emergence of the platinum compounds in the 1970s (Brodovsky
et al, 1984; Klaassen et al, 1988; Young et al, 1990; Wadler et al,
1996). Response rates to oral melphalan ranged from 15 to 40% in
advanced disease (stage III/IV). The efficacy of melphalan in the
setting of relapsed disease has not been explored sufficiently (Pater
et al, 1987). In this retrospective analysis, we investigate the
effectiveness of oral melphalan as salvage therapy in patients who
progressed after platinum-based chemotherapy. The rationale for
using melphalan as a second-line agent was its proven efficacy in
platinum-naı ¨ve patients, ease of administration and tolerability.
METHODS
The aim of the study was to assess objective tumour response rates
in women treated with oral melphalan as second-line therapy after
initial platinum therapy for epithelial ovarian cancer and to assess
the impact of oral melphalan on relapse-free survival and overall
survival in relapsed platinum-resistant epithelial ovarian cancer.
All cases of ovarian carcinoma treated with oral melphalan at the
Department of Medical Oncology at Christie Hospital between
1995 and 2001 inclusive were retrieved from a computerised
database. Oral melphalan was offered to all patients fit to receive
treatment. Of the 40 patients treated with oral melphalan, data
from 22 patients who had platinum-resistant disease were obtained
and retrospectively analysed for the study. Patients who received
melphalan as first-line therapy or after two courses of platinum-
based chemotherapy (n¼18) were excluded from analysis. At this
time the newer drugs, listed earlier, were not used for the treatment
of platinum-resistant disease and therefore most patients who
developed early recurrence were treated with melphalan.
Data collected included age at diagnosis, histological subtype of
ovarian carcinoma, details of primary treatment including surgery,
response rates to primary treatment and PFIs, salvage treatment
and treatment-related toxicity. Responses were assessed clinically, Received 23 August 2002; revised 19 April 2003; accepted 22 April 2003
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lradiologically by CT scanning and biochemically by CA125
measurements. Response rates were defined according to WHO
criteria.
Treatment protocol
Melphalan was given orally at 10mg a day for 5 days repeated
every 6 weeks for six cycles. Pretreatment evaluation consisted of a
physical examination, full blood count, biochemical profile (renal
and liver function tests), CA125 measurements and baseline
staging CT. All patients were required to have adequate
haematological reserve prior to commencement of treatment. Full
blood count and biochemistry were monitored at three weekly
intervals. Restaging CT was performed at the end of treatment or
where disease progression was suspected on clinical grounds or on
the basis of a rising CA125. All patients gave informed consent for
the treatment.
Treatment was discontinued after six completed cycles or on
account of progressive disease, treatment-related toxicity or
patient death. The primary study end point was to determine the
percentage of patients who achieve an objective tumour response
in terms of a complete response, partial response stable or
progressive disease.
RESULTS
The median age of the 22 patients evaluated was 62 (range 28–78).
Four different platinum-based chemotherapeutic regimens were
used as first-line therapy – single-agent carboplatin (54.5%),
combination chemotherapy consisting of carboplatin/cyclopho-
sphamide (4.5%), carboplatin/paclitaxel (36.3%) or carboplatin/
docetaxel (4.5%). The overall response rate to first-line therapy
was 68%. The median PFI was 4 months (range 0–6).
The median number of cycles of melphalan administered per
patient was 2 (range, 1–6). Only one patient (4.5%) managed to
complete the full complement of six cycles and had radiologically
proven progressive disease at the end of treatment. No objective
radiological responses were observed in any of the 22 patients on
the study. As none of the 22 patients experienced an objective
response to treatment, no relapse-free survival was observed. In
all, 10 patients subsequently went on to third-line chemotherapy or
endocrine therapy. The median overall survival from the
commencement of oral melphalan was 3 months (range, 0–20
months). A total of 15 (68%) patients died within 6 months of
discontinuation of melphalan therapy. At the time of analysis, two
our of 22 patients were still alive and these were being treated
within the context of phase I/II studies.
In general, oral melphalan appeared to be well tolerated. The 22
patients received 44 completed cycles of oral melphalan. There
were seven episodes of grade III/IV haematological toxicity. A total
of three episodes of blood transfusions and two episodes of platelet
transfusions were recorded. Febrile neutropenic episodes were not
seen. Nonhaematological toxicities were infrequent, grade I/II
nausea being the most common. No patient was required to
discontinue treatment on account of toxicity. No treatment-related
mortality was recorded.
DISCUSSION
In this study, we evaluated the efficacy of oral melphalan as
second-line therapy for relapsed epithelial ovarian carcinoma
following platinum failure. There were no responses in the study
population. Melphalan had no impact on the relapse-free survival
or overall survival of patients. However, on closer analysis of
the data, some important points emerge. The entire patient
population in the study belonged to a poor prognosis group. The
most important point is that the median PFI following first-line
platinum-based therapy was only 3 months (range 0–6). Thus,
all patients had chemoresistant or refractory disease and
were therefore likely to fare poorly irrespective of the chemo-
therapeutic agent adopted. Given the patient numbers in the
platinum-resistant and refractory subgroup, it is unlikely that
any objective response would have been missed by chance (95%
CI 0–15.44).
Only six patients had undergone optimum debulking surgery
following initial diagnosis and the vast majority of patients had a
high tumour burden (42 lesions – 95.4% and 45cm – 50%),
both of which are well-recognised poor prognostic indicators in
relapsed disease. However, data from studies with other agents
active in platinum-resistant/refractory disease have shown re-
sponse rates of 20% and response durations of 6–8 months, and
although a direct comparison is not possible oral melphalan does
appear inferior in this situation. The treatment regimen also needs
to be evaluated. The incidence of grade III/IV haematological
toxicity in the patient population was 16% with the treatment
regimen employed (10mg daily for 5 days repeated every 6 weeks).
Although the treatment in general was well tolerated, a more dose-
intense (6–8mgm
 2day
 1) and a more dose-dense regimen,
perhaps a 4-weekly rather than a 6-weekly cycle merits considera-
tion. However, significant myelosuppression was recorded sug-
gesting that this dose and schedule approach the maximum
tolerated dose of melphalan.
Despite the retrospective nature of the study, the data suggest
that melphalan has poor activity as salvage therapy following
platinum failure in relapsed epithelial ovarian cancer and should
not be considered for patients with platinum-resistant/refractory
disease. Further well-designed randomised controlled trials are
needed to define the optimum management for patients with
relapsed epithelial ovarian cancers.
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